The feasibility study of FOLFOX therapy in gastrointestinal cancer patients undergoing hemodialysis

The multicenter clinical trial to investigate the safety and efficacy of FOLFOX therapy in gastrointestinal cancer patients undergoing hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051190120

Enrollment

Registered

2020-03-11

Start date

2020-03-23

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer, gastric cancer, small bowel cancer, colorectal cancer

Interventions

FOLFOX therapy

Antineoplastic Combined Chemotherapy Protocols

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing hemodialysis. 2. Patients diagnosed as gastrointestinal cancer. 3. Less than 80years old, and PS is 0-1. 4. Organ functions other than renal function are maintained. 5. Chemotherapy naive case. 6. The written consent can be obtained from patients.

Exclusion criteria

Exclusion criteria: 1. Hyperammonemia within 14 days befere registration. 2. Patients with Grade 2 peripheral sensory neuropathy.

Design outcomes

Primary

Measure	Time frame
Part1 : Recommended starting dose Part2: Completion rate of chemotherapy	—

Secondary

Measure	Time frame
Overall survival, Response rate, incidence of adverse events	—

Contacts

Public ContactKataoka Shigeki

Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University

skataoka@kuhp.kyoto-u.ac.jp+81-75-751-4392

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026